


Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.


Listing of Claims

1. (Original) A compound of the formula:




or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, wherein each of R_1 and R_2 is independently lower alkyl or hydrogen, and each of R_3 , R_4 , and R_5 is independently hydrogen, hydroxyl, or alkoxy, provided that: at least one of R_3 , R_4 , and R_5 is not hydrogen; if each of R_1 , R_2 , R_4 , and R_5 is hydrogen and R_3 is hydroxyl, the compound is not racemic; and if each of R_1 , R_2 , R_3 , and R_4 is hydrogen and R_5 is hydroxyl, the compound is not racemic.

2. (Currently Amended) A compound of the formula:




or a pharmaceutically ~~acceptable~~, acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, wherein each of R_1 and R_2 is independently alky or hydrogen, provided that if R_1 and R_2 are both hydrogen, the compound is not racemic.

3. (Currently Amended) A compound of the formula:



or a pharmaceutically ~~acceptable~~, acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, wherein each of R₁ and R₂ is independently alkyl or hydrogen.

4. (Currently Amended) A compound of the formula:



or a pharmaceutically ~~acceptable~~, acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, wherein each of R₁ and R₂ is independently alkyl or hydrogen, provided that if both R₁ and R₂ are hydrogen, the compound is not racemic.

5. (Original) The compound of claim 1, 2, 3, or 4, wherein at least one of R₁ or R₂ is hydrogen.


6. (Original) The compound of claim 1, 2, 3, or 4, wherein at least one of R₁ or R₂ is methyl.

7. (Original) The compound of claim 1, 2, 3, or 4, wherein the compound is stereomerically pure.

8. (Original) The compound of claim 1, 2, 3, or 4, wherein the compound is an enantiomeric or diastereomeric mixture that is not a racemic mixture.

Claims 9-31. (Canceled without prejudice)

32. (Original) A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a racemic or stereomerically pure compound of formula:



or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, wherein each of R_1 and R_2 is independently lower alkyl or hydrogen, and each of R_3 , R_4 , and R_5 is independently hydrogen, hydroxyl, or alkoxy, provided that at least one of R_3 , R_4 , and R_5 is not hydrogen.

33. (Original) The pharmaceutical composition of claim 32, wherein if R_1 , R_2 , R_4 , and R_5 are each hydrogen and R_3 is hydroxyl, the compound is not racemic, and if R_1 , R_2 , R_3 , and R_4 are each hydrogen and R_5 is hydroxyl, the compound is not racemic.

34. (Original) The pharmaceutical composition of claim 32, wherein at least one of R_1 or R_2 is hydrogen and at least one of R_3 , R_4 , or R_5 is hydroxyl.

35. (Original) The pharmaceutical composition of claim 32, wherein at least one of R_1 or R_2 is methyl and at least one of R_3 , R_4 , or R_5 is hydroxyl.

36. (Original) The pharmaceutical composition of claim 32, wherein the compound is stereomerically pure.

37. (Original) The pharmaceutical composition of claim 32, wherein the compound is an enantiomeric or diastereomeric mixture that is not racemic.

38. (Original) The pharmaceutical composition of claim 32, wherein the compound is hydroxylated sibutramine or a hydroxylated sibutramine metabolite.

39. (Original) The pharmaceutical composition of claim 38, wherein the compound is hydroxylated in the 1-position.

40. (Original) The pharmaceutical composition of claim 38, wherein the compound is hydroxylated in the 3-position.

41. (Original) The pharmaceutical composition of claim 38, wherein the compound is hydroxylated in the 7-position.

42. (Original) The pharmaceutical composition of claim 32, wherein the pharmaceutical composition is adapted for oral, mucosal, rectal, parenteral, or transdermal administration.

43. (Original) The pharmaceutical composition of claim 32, wherein said composition is lactose-free.

Claims 44-73. (Canceled without prejudice)